Protein Kinase Cι Drives a NOTCH3-dependent Stem-like Phenotype in Mutant KRAS Lung Adenocarcinoma

Cancer Cell

Volumn 29, Issue 3, 2016, Pages 367-378

  Ali, Syed A ^a   Justilien, Verline ^a   Jamieson, Lee ^a   Murray, Nicole R ^a   Fields, Alan P ^a  

^a MAYO CLINIC   (United States)

Author keywords

ELF3; KRAS driven lung adenocarcinoma; NOTCH signaling; Protein kinase C ; Therapeutic intervention

Indexed keywords

AURANOFIN; GAMMA SECRETASE INHIBITOR; NOTCH3 RECEPTOR; PROTEIN KINASE C IOTA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ELF3; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; ELF3 PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; NOTCH RECEPTOR; NOTCH3 PROTEIN, HUMAN; PROTEIN KINASE C; PROTEIN P21; TRANSCRIPTION FACTOR ETS;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASYMMETRIC CELL DIVISION; CANCER INHIBITION; CANCER STEM CELL; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; MOUSE; NONHUMAN; ONCOGENE K RAS; ONCOSPHERE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ADENOCARCINOMA; CELL TRANSFORMATION; GENETICS; LUNG TUMOR; METABOLISM; MUTATION; STEM CELL; TUMOR CELL LINE;

ADENOCARCINOMA; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASTIC STEM CELLS; PHENOTYPE; PROMOTER REGIONS, GENETIC; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS C-ETS; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, NOTCH3; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; STEM CELLS; TRANSCRIPTION FACTORS;

EID: 84962886830     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.02.012     Document Type: Article

References (62)

1. Atwood S.X., Li M., Lee A., Tang J.Y., Oro A.E. GLI activation by atypical protein kinase C iota/lambda regulates the growth of basal cell carcinomas. Nature 2013, 494:484-488.
2. Butler A.M., Scotti Buzhardt M.L., Erdogan E., Li S., Inman K.S., Fields A.P., Murray N.R. A small molecule inhibitor of atypical protein kinase C signaling inhibits pancreatic cancer cell transformed growth and invasion. Oncotarget 2015, 6:15297-15310.
3. Cerami E., Gao J., Dogrusoz U., Gross B.E., Sumer S.O., Aksoy B.A., Jacobsen A., Byrne C.J., Heuer M.L., Larsson E., et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012, 2:401-404.
4. Chiorean E.G., LoRusso P., Strother R.M., Diamond J.R., Younger A., Messersmith W.A., Adriaens L., Liu L., Kao R.J., DiCioccio A.T., et al. A phase I first-in-human study of enoticumab (REGN421), a fully human Delta-like Ligand 4 (Dll4) monoclonal antibody in patients with advanced solid tumors. Clin. Cancer Res. 2015, 21:2695-2703.
5. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
6. Clarke M.F., Dick J.E., Dirks P.B., Eaves C.J., Jamieson C.H., Jones D.L., Visvader J., Weissman I.L., Wahl G.M. Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res. 2006, 66:9339-9344.
7. Eramo A., Lotti F., Sette G., Pilozzi E., Biffoni M., Di Virgilio A., Conticello C., Ruco L., Peschle C., De Maria R. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008, 15:504-514.
8. Erdogan E., Lamark T., Stallings-Mann M., Lee J., Pellecchia M., Thompson E.A., Johansen T., Fields A.P. Aurothiomalate inhibits transformed growth by targeting the PB1 domain of protein kinase Ciota. J. Biol. Chem. 2006, 281:28450-28459.
9. Erdogan E., Klee E.W., Thompson E.A., Fields A.P. Meta-analysis of oncogenic protein kinase Ciota signaling in lung adenocarcinoma. Clin. Cancer Res. 2009, 15:1527-1533.
10. Fan X., Matsui W., Khaki L., Stearns D., Chun J., Li Y.M., Eberhart C.G. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res. 2006, 66:7445-7452.
11. Fan X., Khaki L., Zhu T.S., Soules M.E., Talsma C.E., Gul N., Koh C., Zhang J., Li Y.M., Maciaczyk J., et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 2010, 28:5-16.
12. Fields A.P., Frederick L.A., Regala R.P. Targeting the oncogenic protein kinase Ciota signalling pathway for the treatment of cancer. Biochem. Soc. Trans. 2007, 35:996-1000.
13. Flaherty K.T., Infante J.R., Daud A., Gonzalez R., Kefford R.F., Sosman J., Hamid O., Schuchter L., Cebon J., Ibrahim N., et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 2012, 367:1694-1703.
14. Frederick L.A., Matthews J.A., Jamieson L., Justilien V., Thompson E.A., Radisky D.C., Fields A.P. Matrix metalloproteinase-10 is a critical effector of protein kinase Ciota-Par6alpha-mediated lung cancer. Oncogene 2008, 27:4841-4853.
15. Gao J., Aksoy B.A., Dogrusoz U., Dresdner G., Gross B., Sumer S.O., Sun Y., Jacobsen A., Sinha R., Larsson E., et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal 2013, 6:pl1.
16. Groeneweg J.W., DiGloria C.M., Yuan J., Richardson W.S., Growdon W.B., Sathyanarayanan S., Foster R., Rueda B.R. Inhibition of notch signaling in combination with Paclitaxel reduces platinum-resistant ovarian tumor growth. Front. Oncol. 2014, 4:171.
17. Groeneweg J.W., Foster R., Growdon W.B., Verheijen R., Rueda B.R. Notch signaling in serous ovarian cancer. J. Ovarian Res. 2014, 7:95.
18. Guo W., Wu S., Liu J., Fang B. Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota. Cancer Res. 2008, 68:7403-7408.
19. Hassan K.A., Wang L., Korkaya H., Chen G., Maillard I., Beer D.G., Kalemkerian G.P., Wicha M.S. Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clin. Cancer Res. 2013, 19:1972-1980.
20. Herbst R.S. Targeted therapy using novel agents in the treatment of non-small-cell lung cancer. Clin. Lung Cancer 2002, 3(Suppl 1):S30-S38.
21. Jatoi A., Radecki Breitkopf C., Foster N.R., Block M.S., Grudem M., Wahner Hendrickson A., Carlson R.E., Barrette B., Karlin N., Fields A.P. A mixed-methods feasibility trial of protein kinase C iota inhibition with auranofin in asymptomatic ovarian cancer patients. Oncology 2014, 88:208-213.
22. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
23. Justilien V., Fields A.P. Ect2 links the PKCiota-Par6alpha complex to Rac1 activation and cellular transformation. Oncogene 2009, 28:3597-3607.
24. Justilien V., Fields A.P. Molecular pathways: novel approaches for improved therapeutic targeting of hedgehog signaling in cancer stem cells. Clin. Cancer Res. 2015, 21:505-513.
25. Justilien V., Jameison L., Der C.J., Rossman K.L., Fields A.P. Oncogenic activity of Ect2 is regulated through protein kinase C iota-mediated phosphorylation. J. Biol. Chem. 2011, 286:8149-8157.
26. Justilien V., Regala R.P., Tseng I.C., Walsh M.P., Batra J., Radisky E.S., Murray N.R., Fields A.P. Matrix metalloproteinase-10 is required for lung cancer stem cell maintenance, tumor initiation and metastatic potential. PLoS One 2012, 7:e35040.
27. Justilien V., Walsh M.P., Ali S.A., Thompson E.A., Murray N.R., Fields A.P. The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma. Cancer Cell 2014, 25:139-151.
28. Kalari K.R., Rossell D., Necela B.M., Asmann Y.W., Nair A., Baheti S., Kachergus J.M., Younkin C.S., Baker T., Carr J.M., et al. Deep sequence analysis of non-small cell lung cancer: integrated analysis of gene expression, alternative splicing, and single nucleotide variations in lung adenocarcinomas with and without oncogenic KRAS mutations. Front. Oncol. 2012, 2:12.
29. Koivunen J.P., Mermel C., Zejnullahu K., Murphy C., Lifshits E., Holmes A.J., Choi H.G., Kim J., Chiang D., Thomas R., et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res. 2008, 14:4275-4283.
30. Konishi J., Kawaguchi K.S., Vo H., Haruki N., Gonzalez A., Carbone D.P., Dang T.P. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res. 2007, 67:8051-8057.
31. Kreso A., Dick J.E. Evolution of the cancer stem cell model. Cell Stem Cell 2014, 14:275-291.
32. Kwong L.N., Costello J.C., Liu H., Jiang S., Helms T.L., Langsdorf A.E., Jakubosky D., Genovese G., Muller F.L., Jeong J.H., et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat. Med. 2012, 18:1503-1510.
33. Lathia J.D., Hitomi M., Gallagher J., Gadani S.P., Adkins J., Vasanji A., Liu L., Eyler C.E., Heddleston J.M., Wu Q., et al. Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions. Cell Death Dis. 2011, 2:e200.
34. Le Good J.A., Ziegler W.H., Parekh D.B., Alessi D.R., Cohen P., Parker P.J. Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science 1998, 281:2042-2045.
35. Lin D., Edwards A.S., Fawcett J.P., Mbamalu G., Scott J.D., Pawson T. A mammalian PAR-3-PAR-6 complex implicated in Cdc42/Rac1 and aPKC signalling and cell polarity. Nat. Cell Biol. 2000, 2:540-547.
36. Mackereth C.D., Scharpf M., Gentile L.N., MacIntosh S.E., Slupsky C.M., McIntosh L.P. Diversity in structure and function of the Ets family PNT domains. J. Mol. Biol. 2004, 342:1249-1264.
37. Mah I.K., Soloff R., Hedrick S.M., Mariani F.V. Atypical PKC-iota controls stem cell expansion via regulation of the notch pathway. Stem Cell Rep. 2015, 5:866-880.
38. Mansfield A.S., Fields A.P., Jatoi A., Qi Y., Adjei A.A., Erlichman C., Molina J.R. Phase I dose escalation study of the PKCiota inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer. Anticancer Drugs 2013, 24:1079-1083.
39. Messersmith W.A., Shapiro G.I., Cleary J.M., Jimeno A., Dasari A., Huang B., Shaik M.N., Cesari R., Zheng X., Reynolds J.M., et al. A phase I, dose-finding study in patients with advanced solid malignancies of the oral gamma-secretase inhibitor PF-03084014. Clin. Cancer Res. 2015, 21:60-67.
40. Morrison S.J., Kimble J. Asymmetric and symmetric stem-cell divisions in development and cancer. Nature 2006, 441:1068-1074.
41. Nakajima T., Kimura H., Takeuchi K., Soda M., Mano H., Yasufuku K., Iizasa T. Treatment of lung cancer with an ALK inhibitor after EML4-ALK fusion gene detection using endobronchial ultrasound-guided transbronchial needle aspiration. J. Thorac. Oncol. 2010, 5:2041-2043.
42. Neumuller R.A., Knoblich J.A. Dividing cellular asymmetry: asymmetric cell division and its implications for stem cells and cancer. Genes Dev. 2009, 23:2675-2699.
43. Ohno S. Intercellular junctions and cellular polarity: the PAR-aPKC complex, a conserved core cassette playing fundamental roles in cell polarity. Curr. Opin. Cell Biol. 2001, 13:641-648.
44. Oliver J.R., Kushwah R., Wu J., Pan J., Cutz E., Yeger H., Waddell T.K., Hu J. Elf3 plays a role in regulating bronchiolar epithelial repair kinetics following Clara cell-specific injury. Lab. Invest. 2011, 91:1514-1529.
45. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., Singh B., Heelan R., Rusch V., Fulton L., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 2004, 101:13306-13311.
46. Pine S.R., Ryan B.M., Varticovski L., Robles A.I., Harris C.C. Microenvironmental modulation of asymmetric cell division in human lung cancer cells. Proc. Natl. Acad. Sci. USA 2010, 107:2195-2200.
47. Regala R.P., Weems C., Jamieson L., Copland J.A., Thompson E.A., Fields A.P. Atypical protein kinase Ciota plays a critical role in human lung cancer cell growth and tumorigenicity. J. Biol. Chem. 2005, 280:31109-31115.
48. Regala R.P., Weems C., Jamieson L., Khoor A., Edell E.S., Lohse C.M., Fields A.P. Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer. Cancer Res. 2005, 65:8905-8911.
49. Regala R.P., Thompson E.A., Fields A.P. Atypical protein kinase C iota expression and aurothiomalate sensitivity in human lung cancer cells. Cancer Res. 2008, 68:5888-5895.
50. Regala R.P., Davis R.K., Kunz A., Khoor A., Leitges M., Fields A.P. Atypical protein kinase C{iota} is required for bronchioalveolar stem cell expansion and lung tumorigenesis. Cancer Res. 2009, 69:7603-7611.
51. Roper K., Corbeil D., Huttner W.B. Retention of prominin in microvilli reveals distinct cholesterol-based lipid micro-domains in the apical plasma membrane. Nat. Cell Biol. 2000, 2:582-592.
52. Scotti M.L., Smith K.E., Butler A.M., Calcagno S.R., Crawford H.C., Leitges M., Fields A.P., Murray N.R. Protein kinase C iota regulates pancreatic acinar-to-ductal metaplasia. PLoS One 2012, 7:e30509.
53. Stallings-Mann M., Jamieson L., Regala R.P., Weems C., Murray N.R., Fields A.P. A novel small-molecule inhibitor of protein kinase Ciota blocks transformed growth of non-small-cell lung cancer cells. Cancer Res. 2006, 66:1767-1774.
54. Standaert M.L., Bandyopadhyay G., Perez L., Price D., Galloway L., Poklepovic A., Sajan M.P., Cenni V., Sirri A., Moscat J., et al. Insulin activates protein kinases C-zeta and C-lambda by an autophosphorylation-dependent mechanism and stimulates their translocation to GLUT4 vesicles and other membrane fractions in rat adipocytes. J. Biol. Chem. 1999, 274:25308-25316.
55. Sullivan J.P., Spinola M., Dodge M., Raso M.G., Behrens C., Gao B., Schuster K., Shao C., Larsen J.E., Sullivan L.A., et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res. 2010, 70:9937-9948.
56. Tatsumori T., Tsuta K., Masai K., Kinno T., Taniyama T., Yoshida A., Suzuki K., Tsuda H. p40 is the best marker for diagnosing pulmonary squamous cell carcinoma: comparison with p63, cytokeratin 5/6, desmocollin-3, and sox2. Appl. Immunohistochem. Mol. Morphol. 2014, 22:377-382.
57. Vasan N., Boyer J.L., Herbst R.S. A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer. Clin. Cancer Res. 2014, 20:3921-3930.
58. Vorhagen S., Niessen C.M. Mammalian aPKC/Par polarity complex mediated regulation of epithelial division orientation and cell fate. Exp. Cell Res. 2014, 328:296-302.
59. Wang Y., Hill K.S., Fields A.P. Protein kinase Ciota maintains a tumor-initiating cell phenotype that is required for ovarian tumorigenesis. Mol. Cancer Res. 2013, 11:1624-1635.
60. Weigmann A., Corbeil D., Hellwig A., Huttner W.B. Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. Proc. Natl. Acad. Sci. USA 1997, 94:12425-12430.
61. Yuan P., Kadara H., Behrens C., Tang X., Woods D., Solis L.M., Huang J., Spinola M., Dong W., Yin G., et al. Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One 2010, 5:e9112.
62. Zheng Y., de la Cruz C.C., Sayles L.C., Alleyne-Chin C., Vaka D., Knaak T.D., Bigos M., Xu Y., Hoang C.D., Shrager J.B., et al. A rare population of CD24(+)ITGB4(+)Notch(hi) cells drives tumor propagation in NSCLC and requires Notch3 for self-renewal. Cancer Cell 2013, 24:59-74.